XNAS
CRVO
Market cap30mUSD
Oct 08, Last price
3.28USD
1D
3.14%
1Q
-8.12%
Jan 2017
-99.87%
IPO
-99.93%
Name
Diffusion Pharmaceuticals Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
65.98%
Rev. gr., 5y
%
Revenues
0
Net income
-27m
L+65.53%
CFO
-23m
L+41.86%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
As a biopharmaceutical enterprise, Diffusion Pharmaceuticals Inc. concentrates on pioneering new treatments that bolster the body's efficiency in oxygen distribution. The company's flagship investigational therapy is Trans Sodium Crocetinate, which is formulated to facilitate the spread of oxygen into tissues. This compound is additionally under development for its application in addressing COVID-19. Headquartered in Charlottesville, Virginia, Diffusion Pharmaceuticals Inc. was established in 2001.
Legal address
C/O National Corporate Research, Ltd.
850 New Burton Road
Suite 201
Dover, DE 19904
US
850 New Burton Road
Suite 201
Dover, DE 19904
US
Headquarters
2020 Avon Court
Suite 4
Charlottesville, VA 22902
US
Suite 4
Charlottesville, VA 22902
US
Previous name
RestorGenex Corporation
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||